Recently, Medtronic expanded its cardiac portfolio by introducing the PulseSelect system in India. Consequently, Indian cardiologists now have access to this next-generation pulsed field ablation technology to treat atrial fibrillation. Atrial fibrillation remains a severely underdiagnosed heart rhythm disorder that affects millions of people across the country. However, traditional thermal therapies like radiofrequency ablation often carry a small risk of collateral tissue damage. To solve this issue, the novel system delivers short electrical pulses instead of extreme heat or cold. This non-thermal mechanism successfully isolates the pulmonary veins while protecting nearby sensitive structures.
How Pulsed Field Ablation Enhances Patient Safety
Specifically, the system targets cardiac cells using a high-voltage electrical field. Because it avoids thermal energy, it prevents injury to the esophagus and surrounding nerves. Therefore, physicians can perform the procedure more safely and quickly than before. In addition, clinical studies have already demonstrated the system’s exceptional safety profile globally. Meanwhile, Indian hospitals are already integrating this breakthrough into their routine electrophysiology workflows.
Addressing the Growing Burden of AFib in India
India is witnessing a significant rise in stroke cases and complex cardiac diseases. As a result, expanding advanced therapeutic options is critical for improving patient outcomes. Furthermore, many patients ignore mild symptoms, which unfortunately delays their diagnosis and care. Medtronic aims to bridge this care gap by supporting healthcare providers with high-precision tools. Ultimately, this innovation will help reduce stroke risks and enhance the overall quality of life for those pursuing an advanced career in cardiology.
Frequently Asked Questions
Q1: What is pulsed field ablation?
Pulsed field ablation is a non-thermal cardiac ablation technique that uses controlled electrical pulses to target abnormal heart tissue while sparing adjacent structures.
Q2: How does the PulseSelect system reduce procedural risks?
The device avoids extreme temperatures, which significantly lowers the risk of damaging nearby tissues like the esophagus or phrenic nerve.
References
- Medtronic launches device to treat atrial fibrillation – ETHealthworld
- Medtronic Introduces PulseSelect™ PFA Technology to address India’s Growing AFib and Stroke Burden – Medtronic Press Release
- Kauvery Hospitals Launches Advanced Pulsed Field Ablation Systems in Chennai for Atrial Fibrillation Treatment in Tamil Nadu – ANI News
Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.